SCHEMBL21422293

SCHEMBL21422293

O=C(O)CCOCCOCCOCCOCCOC(=O)CCCCC1SCC2NC(=O)NC21

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 6/20 0.70
▸ PKM P14618 2/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ ABL1 P00519 1/20 0.70
▸ LMNA P02545 1/20 0.70
▸ IDE P14735 1/20 0.70
▸ MAPK1 P28482 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ RIN1 Q13671 1/20 0.70
▸ L3MBTL1 Q9Y468 1/20 0.70
▸ FOLH1 Q04609 3/20 0.55
▸ HLCS P50747 6/20 0.53
▸ HPSE Q9Y251 1/20 0.52
▸ F2 P00734 1/20 0.49
▸ PRSS1 P07477 1/20 0.49
▸ PRSS2 P07478 1/20 0.49
▸ PRSS3 P35030 1/20 0.49
▸ TPSAB1 Q15661 1/20 0.49
▸ CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7157942 0.91 TDP1 (0.77) TDP1PKMMEN1ABL1LMNA
SCHEMBL4804477 0.90 TDP1 (0.66) TDP1PKMMEN1ABL1LMNA
SCHEMBL4461491 0.90 TDP1 (0.66) TDP1PKMMEN1ABL1LMNA
SCHEMBL17458950 0.90 TDP1 (0.66) TDP1PKMMEN1ABL1LMNA
SCHEMBL14247914 0.90 TDP1 (0.66) TDP1PKMMEN1ABL1LMNA
SCHEMBL28163095 0.89 TDP1 (0.65) TDP1PKMMEN1ABL1LMNA
SCHEMBL19608935 0.89 TDP1 (0.73) TDP1PKMMEN1ABL1LMNA
SCHEMBL19803917 0.88 TDP1 (0.72) TDP1PKMMEN1ABL1LMNA
SCHEMBL24846705 0.88 FOLH1 (0.65) TDP1PKMMEN1ABL1LMNA
SCHEMBL23169832 0.88 FOLH1 (0.65) TDP1PKMMEN1ABL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190300590-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. 2019-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300590-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL1RN, VIP TDP1 4424/4885PKM 4457/4885MEN1 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback